• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Aurobindo Pharma Ltd.
    26 Aug 2025
    1119.20
    -0.86%
    Aurobindo unit gets UK nod for biosimilar breast cancer drug Dazublys
    Business Standard
    CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has secured UK MHRA approval for its trastuzumab biosimilar Dazublys, used in HER2-positive breast and gastric cancer treatment
    Copy LinkShare onShare on Share on Share on
    Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings
    logo
    Indoco Remedies Ltd.
    26 Aug 2025
    301.95
    0.07%
    Nirmal Bang Remains Structurally Positive On Indoco Remedies; Maintains 'Hold' Rating Check Target Price
    Nirmal Bang Remains Structurally Positive On Indoco Remedies; Maintains 'Hold' Rating Check Target Price
    NDTV Profit
    Nirmal Bang values the company at 11x Jul-27E EV/Ebitda and maintain Hold rating on Indoco Remedies, resulting in a target price of Rs 310.
    Copy LinkShare onShare on Share on Share on
    Indoco Remedies Ltd. has gained 30.68% in the last 6 Months
    logo
    Sun Pharmaceutical Industries Ltd.
    26 Aug 2025
    1656.00
    0.45%
    Sun Pharma shares slip 3% after BofA downgrade on premium valuations
    Sun Pharma shares slip 3% after BofA downgrade on premium valuations
    Economic Times
    Bank of America downgraded Sun Pharma stock to underperform' from neutral', citing risks to premium valuations and slower speciality execution. The brokerage cut its target price, flagging concerns over Ilumya's Medicare exposure, pricing pressures, and limited earnings visibility despite strong initial performance.
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical Industries Ltd. is trading above its 50 day SMA of 1639.2
    logo
    Senores Pharmaceuticals Ltd.
    25 Aug 2025
    712.30
    -0.54%
    Broker's call: Senores Pharma (Buy)
    Business Line
    Choice International
    Copy LinkShare onShare on Share on Share on
    Senores Pharmaceuticals Ltd. has gained 82.17% in the last 1 Year
    logo
    Akums Drugs & Pharmaceuticals Ltd.
    25 Aug 2025
    476.50
    0.33%
    Akums Drugs announces JV to set up manufacturing facility in Zambia
    Business Standard
    Akums will hold 51% in its joint venture with the Zambian government to set up a pharma manufacturing facility, marking its first overseas plant and Africa expansion
    Copy LinkShare onShare on Share on Share on
    Akums Drugs & Pharmaceuticals Ltd. has lost -43.63% in the last 1 Year
    logo
    Sai Life Science Ltd.
    25 Aug 2025
    913.65
    2.12%
    Cohance Lifesciences and other pharma stocks jump up to 5% after Jefferies initiates Buy recommendation
    Cohance Lifesciences and other pharma stocks jump up to 5% after Jefferies initiates Buy recommendation
    Economic Times
    Cohance Lifesciences, Divi's Laboratories, and SAI Life Sciences rallied after Jefferies initiated coverage with Buy' ratings, citing strong growth prospects in India's CRDMO sector. The brokerage sees a high-teen revenue CAGR, led by China+1 diversification, pipeline visibility, and demand for diabetes and weight-loss therapies.
    Copy LinkShare onShare on Share on Share on
    Sai Life Science Ltd. has gained 23.73% in the last 3 Months
    logo
    Cipla Ltd.
    22 Aug 2025
    1575.80
    -0.15%
    Five Stocks To Buy Today: Devyani, Cipla, IndusInd Bank And OthersCheck Target Price
    Five Stocks To Buy Today: Devyani, Cipla, IndusInd Bank And OthersCheck Target Price
    NDTV Profit
    The stock recommendations come with specific target price and stop loss price.
    Copy LinkShare onShare on Share on Share on
    Cipla Ltd. has an average target of 1702.60 from 10 brokers.
    logo
    Cipla Ltd.
    22 Aug 2025
    1575.80
    -0.15%
    Looking for short-term F&O trade? Check this 'Bull Spread' on Cipla
    Business Standard
    Short term trend is positive as it is placed above its 5, 11 and 20 day EMA Stock price has broken out on the weekly chart with higher volumes
    Copy LinkShare onShare on Share on Share on
    Cipla Ltd. has an average target of 1702.60 from 10 brokers.
    logo
    Caplin Point Laboratories Ltd.
    22 Aug 2025
    2343.00
    0.93%
    Stock Market Live Updates 22 August 2025: Stock to buy today: Caplin Point Laboratories
    Business Line
    Sensex, Nifty, Share Prices LIVE: The short-term outlook is bullish for Caplin Point Laboratories. The 4 per cent rise has taken the share price well above the 2,130-2,140 resistance zone. This region will now act as a good support and limit the downside. Below this 2,080 will be the next important support. Immediate resistance is at 2,230 which can be broken in the next few days. Such a break can take Caplin Point Laboratories share price up to 2,330 in the coming weeks. Traders can buy Caplin Point Laboratories now at 2,205. Accumulate on dips at 2,160. Keep the stop-loss at 2,110 initially. Trail the stop-loss up to 2,225 as soon as the stock goes up to 2,255. Move the stop-loss further up to 2,260 and 2,285 when the price touches 2,280 and 2,300 respectively. Exit the long positions at 2,320.
    Copy LinkShare onShare on Share on Share on
    Caplin Point Laboratories Ltd. is trading above all available SMAs
    Stock to buy today: Caplin Point Laboratories (2,205) BUY
    Business Line | 22 Aug 2025
    logo
    Granules India Ltd.
    22 Aug 2025
    543.40
    0.05%
    Can Granules India leverage its strong product pipeline to offset recent profit declines?
    Can Granules India leverage its strong product pipeline to offset recent profit declines?
    Economic Times
    Granules India's stock shows a slight recovery despite reporting lower profits in the June quarter. Investors are positive about the company's product pipeline and business stabilisation. The company anticipates better growth in FY27. Approvals for six products in Europe are awaited. Granules focuses on CNS, ADHD, and oncology products. The Gagillapur facility remediation is progressing well with US FDA.
    Copy LinkShare onShare on Share on Share on
    Granules India Ltd. is trading above all available SMAs
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • Vms Tmt
    • Sampat Aluminium
    • JD Cables
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd